MedTrace Logo

COVID-19 Vaccine and Ovarian Reserve

NCT04748172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-06-22

No results posted yet for this study

Summary

As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .

Conditions

  • Fertility Issues
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

SARS-CoV-2 virus vaccines

mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)

DIAGNOSTIC_TEST

AMH sampling

Blood sample for AMH on recruitment and after three months

DIAGNOSTIC_TEST

anti Covid-19 antibody levels (Serology)

Blood sample for IgG against S1 protein after three months

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Eligibility

Min Age
11 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748172 on ClinicalTrials.gov